Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Stomach Neoplasms 10Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 5Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1HER2 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

tislelizumab 2Cystectomy 2vistusertib 1toripalimab 1olaparib 1liposomal doxorubicin 1durvalumab 1disitamab vedotin 1danvatirsen 1adavosertib 1Surgical Procedures, Operative 1Rutin 1Radiation 1RC48 antibody 1Neoadjuvant Therapy 1Gemcitabine 1Cisplatin 1Chemoradiotherapy 1AZD4547 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer × disitamab vedotin × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡